
Loading, please wait...

Loading, please wait...

Asthma remains a significant global health burden, characterized by chronic airway inflammation and hypersensitivity. While corticosteroids are the standard of care, long-term administration often leads to undesirable side effects. Consequently, medical researchers are increasingly exploring plant-derived compounds to identify safer therapeutic options. A recent study has highlighted the potential of luteolin for allergic asthma, specifically identifying it as a primary active component within Chamaecrista nomame (CN) extract.
The anti-allergic properties of CN extract stem from its ability to stabilize mast cells. Specifically, researchers utilized bioactivity-guided fractionation to isolate luteolin. This flavonoid effectively modulates FcεRI-mediated signaling, which is a critical pathway in mast cell degranulation. By inhibiting the release of inflammatory mediators like histamine and leukotrienes, luteolin prevents the immediate hypersensitivity reactions typical of asthma attacks. Furthermore, transcriptomic analysis revealed that this compound suppresses proinflammatory cytokine production. It achieves this by downregulating the NF-κB and MAPK signaling pathways, which are pivotal in the immune response cascade.
In a murine model induced by ovalbumin, the CN extract demonstrated impressive efficacy. It markedly reduced airway mucus hypersecretion and immune cell infiltration. Remarkably, the results were comparable to conventional corticosteroid treatments. To establish clinical relevance, the study also tested house dust mite-stimulated human peripheral blood mononuclear cells (PBMCs). Both CN and luteolin significantly inhibited cytokine release in these human cells. Therefore, these natural agents offer a promising avenue for novel asthma therapies that may reduce dependence on synthetic steroids.
The study identifies the plant Chamaecrista nomame as a rich source of luteolin, which was isolated through bioactivity-guided fractionation to confirm its anti-allergic potential.
In animal models, the efficacy of Chamaecrista nomame extract and luteolin in reducing airway inflammation was found to be comparable to corticosteroids, suggesting its potential as a natural alternative.
Luteolin suppresses inflammation by downregulating the NF-κB and MAPK signaling pathways, thereby reducing the production of proinflammatory cytokines and stabilizing mast cells.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Kang TK et al. Anti-Allergic Potential of Chamaecrista nomame and Its Compound Luteolin for Novel Asthma Therapy. Phytother Res. 2026 May 05. doi: 10.1002/ptr.70363. PMID: 42084904.
Wang S et al. Luteolin inhibits autophagy in allergic asthma by activating PI3K/Akt/mTOR signaling and inhibiting Beclin-1-PI3KC3 complex. Int Immunopharmacol. 2021;94:107460.
Quan et al. Regulatory mechanisms of luteolin in inflammatory respiratory diseases. Front Pharmacol. 2024;15:1356090.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Study identifies Chamaecrista nomame and luteolin as potent natural agents for asthma, significantly reducing airway inflammation and mast cell activation....
4 months ago

Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today